Oral VIRAHALT (Novel Immunomodulatory Herbal combination) Compared to standard of care in Subjects with Moderate to Severe COVID-19
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/09/028133
- Lead Sponsor
- K Wellness
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with laboratory-confirmed (PCR) COVID-19 infection
2. Patients with moderate to severe COVID-19 infection (Early warning score >=5)
3. Hospitalized patients in clinical centres
4. Patients with radiology-confirmed pneumonia within the clinical condition of COVID-19 infection including pulmonary opacity
5. Patients with a clinical indication for pneumonia: increased body temperature (defined as a value above >= 36.6�C axillary route, >= 37.2°C oral route or >= 37.8 °C rectal route), dyspnoea, cough and SpO2 <96%
6. Patients aged >=18 years, both genders
7. Patients or LAR able and willing to understand the study, adhere to all study procedures and sign a written Informed Consent Form (ICF) prior to entering the study or with the assistance of the witness
1. Patients not COVID-19 PCR positive
2. Patients with mild COVID-19 infection
3. Patients who are study subjects in another clinical study for another investigational agent for COVID-19
4. Patients with malignant disease and who are treated for malignant diseases in the last 5 years
5. Patients with severe liver and kidney insufficiency (Hepatic enzymes (AST, ALT, ALP): 6. More than three times normal at baseline will be excluded. Bilirubin: More than 2 at baseline will be excluded. GFR: Less than 60 at baseline will be excluded)
7. Patients who are receiving therapy with another experimental immunomodulatory or immunosuppressive agent
8. Patients aged < 18; female patients who are pregnant or breastfeeding
9. Known allergy to study nutraceutical or any component thereof
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method